|
ヤマグチ ジユンイチ
YAMAGUCHI Jiyun'ichi
山口 淳一 所属 医学部 医学科（東京女子医科大学病院） 職種 教授・基幹分野長 |
|
| 論文種別 | その他 |
| 言語種別 | 英語 |
| 査読の有無 | 査読あり |
| 表題 | Comparison of clinical outcomes following percutaneous coronary intervention versus optimal medical therapy based on gray-zone fractional flow reserve in stable angina patients with intermediate coronary artery stenosis (COMFORTABLE prospective study): Study protocol for a multicenter randomized controlled trial. |
| 掲載誌名 | 正式名：Trials 略 称：Trials ISSNコード：17456215 |
| 掲載区分 | 国外 |
| 出版社 | Springer Nature |
| 巻・号・頁 | 20(1),pp.84 |
| 著者・共著者 | Kitabata Hironori, Kubo Takashi, Shiono Yasutsugu, Shimamura Kunihiro, Ino Yasushi, Tanimoto Takashi, Hayashi Yasushi, Komukai Kenichi, Sougawa Hiromichi, Kimura Keizo, Gohda Masahiro, Hashizume Toshikazu, Obana Masahiro, Maeda Kazuisa, Yamaguchi Junichi, Akasaka Takashi |
| 発行年月 | 2019/01 |
| 概要 | BACKGROUND:Even in the current drug-eluting stent era, revascularization for coronary stenosis with fractional flow reserve (FFR) between 0.75 and 0.80, the so-called "gray zone," is a matter of debate. Previous studies have reported conflicting results regarding outcomes of revascularization versus deferral for coronary stenosis when FFR values are in the gray zone, but these studies have had differing designs and populations. We therefore will investigate whether medical therapy plus percutaneous coronary intervention (PCI) is superior to medical therapy alone in reducing major cardiovascular events in patients presenting with coronary stenosis with gray zone FFR values.
METHODS/DESIGN:This is a prospective, multicenter, open-label, parallel group, randomized, controlled, superiority study. A total of 410 eligible participants will be recruited and randomized to either the medical therapy plus PCI group or the medical therapy alone group. The primary endpoint is 1-year major adverse cardiac events (MACEs), defined as a combined endpoint of all-cause death, nonfatal myocardial infarction (MI), or unplanned target vessel revascularization (TVR). Secondary endpoints include MACE at 2 and 5 years. Moreover, each individual component of the primary endpoint, cardiovascular death, target vessel-related and non-target vessel-related MI, all MI, clinically driven TVR or non-TVR, all revascularization, stent thrombosis, and angina symptom status will be evaluated at 1, 2, and 5 years. DISCUSSION:This is the first prospective, multicenter, randomized, controlled study to investigate the superiority of medical therapy plus PCI over medical therapy by itself in reducing major cardiovascular events in patients presenting with coronary stenosis with "gray zone" FFR values. |
| DOI | 10.1186/s13063-019-3182-1 |
| PMID | 30691507 |